Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease

American Journal of Nephrology

Volumn 28, Issue 3, 2008, Pages 397-404

  Karamouzis, Ioannis ^a   Sarafidis, Pantelis A ^a   Karamouzis, Michael ^a   Iliadis, Stavros ^a   Haidich, Anna Bettina ^b   Sioulis, Athanasios ^a   Triantos, Athanasios ^a   Vavatsi Christaki, Norma ^a   Grekas, Dimitrios M ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

15 F2t Isoprostane; Antioxidant capacity, total; Chronic kidney disease; Oxidative stress; Vitamin E

Indexed keywords

15 F2T ISOPROSTANE; 8 ISOPROSTAGLANDIN F2 ALPHA; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARAMETER; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; TOTAL ANTIOXIDANT CAPACITY; VITAMIN BLOOD LEVEL;

ADULT; AGED; ALPHA-TOCOPHEROL; ANTIOXIDANTS; DINOPROST; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 41749091879     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112413     Document Type: Article

References (47)

1. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
3. US Renal Data System: USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2004.
4. Bommer J: Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;17(suppl 11):8-12.
5. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K, Briggs JD: Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003;18:1824-1833.
6. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844-850.
7. Bakris GL: Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005;18:112S-119S.
8. Sarafidis PA, Whalley-Conell A, Sowers JR, Bakris GL: Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr 2006;1:58-65.
9. Sarafidis PA, Grekas DM:Insulin resistance and oxidant stress: an interrelation with deleterious renal consequences? J Cardiometab Syndr 2007;2:139-142.
10. Hayden MR, Whalley-Conell A, Sowers JR: Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005;25:553-569.
11. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000;58:2571-2578.
12. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001;59:1960-1966.
13. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J: Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002;58:190-197.
14. Ozden M, Maral H, Akaydin D, Cetinalp P, Kalender B: Erythrocyte glutathione peroxidase activity, plasma malondialdehyde and erythrocyte glutathione levels in hemodialysis and CAPD patients. Clin Biochem 2002;35:269-273.
15. Himmelfarb J, Hakim RM: Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003;12:593-598.
16. Wilcox CS, Gutterman D: Focus on oxidative stress in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2005;288:H3-H6.
17. Wilcox CS: Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005;289:R913-R935.
18. Sarafidis PA, Ruilope LM: Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006;26:232-244.
19. Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M: Oxidative stress markers in pre-uremic patients. Clin Nephrol 2001;56:308-314.
20. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-1016.
21. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T, Era S: Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 2004;66:1988-1993.
22. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B: Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005;18:721-726.
23. Ha TK, Sattar N, Talwar D, Cooney J, Simpson K, O'Reilly DS, Lean ME: Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJM 1996;89:765-769.
24. Clermont G, Lecour S, Lahet J, Siohan P, Vergely C, Chevet D, Rifle G, Rochette L: Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000;47:618-623.
25. Galli F, Floridi AG, Floridi A, Buoncristiani U: Accumulation of vitamin E metabolites in the blood of renal failure patients. Clin Nutr 2004;23:205-212.
26. Morrow JD: Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-286.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
28. Kampa M, Nistikaki A, Tsaousis V, Maliaraki N, Notas G, Castanas E: A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Clin Pathol 2002;2:3.
29. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42-50.
30. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D: Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48:752-760.
31. Himmelfarb J: Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 2005;23:319-330.
32. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole de SC, Monnier VM, Witztum JL, Kurokawa K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997;100:2995-3004.
33. Miyata T, Sugiyama S, Suzuki D, Inagi R, Kurokawa K: Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Kidney Int Suppl 1999;71:S54-S56.
34. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J: Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000;26:163-176.
35. Komers R, Anderson S: Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003;284:F1121-F1137.
36. Malliaraki N, Mpliamplias D, Kampa M, Perakis K, Margioris AN, Castanas E: Total and corrected antioxidant capacity in hemodialyzed patients. BMC Nephrol 2003;4:4.
37. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD: Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. Kidney Int 2005;68:246-255.
38. Bergesio F, Monzani G, Ciuti R, Pinzani P, Fiaschi N, Priami F, Cirami C, Ciccarelli C, Salvadori M: Total antioxidant capacity (TAC): is it an effective method to evaluate the oxidative stress in uraemia? J Biolumin Chemilumin 1998;13:315-319.
39. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-1218.
40. Akiyama S, Inagaki M, Tsuji M, Gotoh H, Gotoh T, Washio K, Gotoh Y, Oguchi K: Comparison of effect of vitamin E-coated dialyzer and oral vitamin E on hemodialysis-induced Cu/Zn-superoxide dismutase. Am J Nephrol 2005;25:500-506.
41. Stein G, Richter G, Funfstuck R, Sperschneider H, Gunther K: Serum vitamin E levels in patients with chronic renal failure. Int J Artif Organs 1983;6:285-287.
42. Drukker A, Itai T, Stankiewicz H, Goldstein R: Plasma vitamin E levels in uremic children and adolescents. Child Nephrol Urol 1988;9:208-210.
43. Nourooz-Zadeh J: Effect of dialysis on oxidative stress in uraemia. Redox Rep 1999;4:17-22.
44. Sarafidis PA, Bakris GL: Kidney disease and hypertension; in Lip GY, Hall JE (eds): Comprehensive Hypertension. Philadelphia, Mosby Elsevier, 2007, pp 607-619.
45. Sarafidis PA, Khosla N, Bakris GL: Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26.
46. Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N: Olmesartan ameliorates renovascular injury and oxidative stress in zucker obese rats enhanced by dietary protein. Am J Hypertens 2007;20:1085-1091.
47. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R: Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007;18:2945-2952.